Sarah Reddy1, Andrew Strunk1, Amit Garg1. 1. Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.
Abstract
Importance: The overall comorbidity burden among patients with hidradenitis suppurativa (HS) has not been systematically evaluated. Objectives: To investigate the standardized overall comorbidity burden among patients with HS and to compare it with the comorbidity burden in patients with psoriasis and a control group. Design, Setting, and Participants: A cross-sectional analysis was conducted of 5306 patients with HS, 14 037 patients with psoriasis, and 1 733 810 controls identified using electronic health records data from October 1, 2013, through October 1, 2018. Main Outcome and Measure: The primary outcome was the mean Charlson Comorbidity Index (CCI) score. Results: Each matched cohort had 3818 patients (2789 women and 1029 men; mean [SD] age, 45.7 [15.0]). Before matching, the overall mean (SD) CCI score was highest among the psoriasis cohort (2.33 [3.13]), followed by the HS cohort (1.80 [2.79]) and control cohort (1.26 [2.35]). In matched analyses, the overall mean (SD) CCI score was highest among the HS cohort (1.95 [2.96]), followed by the psoriasis cohort (1.47 [2.43]; P < .001) and control cohort (0.95 [1.99]; P < .001) patients. A total of 516 patients with HS (13.5%) had an overall mean CCI score of 5 or greater. Mean CCI score was highest for patients with HS across all sex, race, and age groups. The most common comorbidities among patients with HS were chronic pulmonary disease (1540 [40.3%]), diabetes with chronic complications (365 [9.6%]), diabetes without chronic complications (927 [24.3%]), and mild liver disease (455 [11.9%]). Patients with HS with a CCI score of 5 or greater had 4.97 (95% CI, 1.49-16.63) times the adjusted risk of 5-year mortality compared with patients with HS with a CCI score of zero. Conclusions and Relevance: Patients with HS have a higher overall comorbidity burden compared with patients with psoriasis and a control group. A significant proportion of patients with HS have CCI scores of 5 or greater, which are associated with increased mortality. This degree of comorbidity burden may warrant multidisciplinary implementation of routine screening measures.
Importance: The overall comorbidity burden among patients with hidradenitis suppurativa (HS) has not been systematically evaluated. Objectives: To investigate the standardized overall comorbidity burden among patients with HS and to compare it with the comorbidity burden in patients with psoriasis and a control group. Design, Setting, and Participants: A cross-sectional analysis was conducted of 5306 patients with HS, 14 037 patients with psoriasis, and 1 733 810 controls identified using electronic health records data from October 1, 2013, through October 1, 2018. Main Outcome and Measure: The primary outcome was the mean Charlson Comorbidity Index (CCI) score. Results: Each matched cohort had 3818 patients (2789 women and 1029 men; mean [SD] age, 45.7 [15.0]). Before matching, the overall mean (SD) CCI score was highest among the psoriasis cohort (2.33 [3.13]), followed by the HS cohort (1.80 [2.79]) and control cohort (1.26 [2.35]). In matched analyses, the overall mean (SD) CCI score was highest among the HS cohort (1.95 [2.96]), followed by the psoriasis cohort (1.47 [2.43]; P < .001) and control cohort (0.95 [1.99]; P < .001) patients. A total of 516 patients with HS (13.5%) had an overall mean CCI score of 5 or greater. Mean CCI score was highest for patients with HS across all sex, race, and age groups. The most common comorbidities among patients with HS were chronic pulmonary disease (1540 [40.3%]), diabetes with chronic complications (365 [9.6%]), diabetes without chronic complications (927 [24.3%]), and mild liver disease (455 [11.9%]). Patients with HS with a CCI score of 5 or greater had 4.97 (95% CI, 1.49-16.63) times the adjusted risk of 5-year mortality compared with patients with HS with a CCI score of zero. Conclusions and Relevance: Patients with HS have a higher overall comorbidity burden compared with patients with psoriasis and a control group. A significant proportion of patients with HS have CCI scores of 5 or greater, which are associated with increased mortality. This degree of comorbidity burden may warrant multidisciplinary implementation of routine screening measures.
Authors: Mary E Charlson; Robert E Charlson; Janey C Peterson; Spyridon S Marinopoulos; William M Briggs; James P Hollenberg Journal: J Clin Epidemiol Date: 2008-07-10 Impact factor: 6.437
Authors: Maryam M Asgari; Jashin J Wu; Joel M Gelfand; Craig Salman; Jeffrey R Curtis; Leslie R Harrold; Lisa J Herrinton Journal: Pharmacoepidemiol Drug Saf Date: 2013-05-02 Impact factor: 2.890
Authors: Randi E Foraker; Kathryn M Rose; Eric A Whitsel; Chirayath M Suchindran; Joy L Wood; Wayne D Rosamond Journal: BMC Public Health Date: 2010-10-21 Impact factor: 3.295
Authors: Sofia Löfvendahl; Elke Theander; Åke Svensson; Katarina Steen Carlsson; Martin Englund; Ingemar F Petersson Journal: PLoS One Date: 2014-05-29 Impact factor: 3.240
Authors: Gautham Vellaichamy; Peter Dimitrion; Li Zhou; David Ozog; Henry W Lim; Wilson Liao; Iltefat H Hamzavi; Qing-Sheng Mi Journal: J Invest Dermatol Date: 2021-04-07 Impact factor: 7.590
Authors: Iris González-Villanueva; Cristina DeGracia; Mariana Planells; Inés Poveda; Pedro Álvarez; Luca Schneller-Pavalescu; Isabel Betlloch; Gregor B E Jemec; Jose M Ramos; Jose C Pascual Journal: Acta Derm Venereol Date: 2020-08-18 Impact factor: 3.875
Authors: H B Naik; R Alhusayen; J Frew; S Guilbault; J R Ingram; M A Lowes; A V Marzano; M Paul; B Villumsen; C A Yannuzzi Journal: Br J Dermatol Date: 2020-08-02 Impact factor: 11.113